Samsung Biologics Co.,Ltd. (207940.KS)
| Previous close | 779,000.00 |
| Open | 781,000.00 |
| Bid | 776,000.00 x 0 |
| Ask | 777,000.00 x 0 |
| Day's range | 776,000.00 - 787,000.00 |
| 52-week range | 668,000.00 - 880,000.00 |
| Volume | |
| Avg. volume | 61,854 |
| Market cap | 55.302T |
| Beta (5Y monthly) | 0.51 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Samsung Biologics Reports First Quarter 2024 Financial Results
Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced financial results for the first quarter of fiscal year 2024.
- PR Newswire
Samsung Invests in BrickBio to Develop Advanced Molecules and Therapies Using Protein Engineering Technology for Antibody-Drug Conjugates (ADC)
Samsung Life Science Fund, created jointly between Samsung Biologics (KRX: 207940.KS), Samsung Bioepis, and Samsung C&T (KRX: 028260.KS), and managed by Samsung Ventures, and BrickBio, Inc. announced Samsung's investment in BrickBio, a preclinical-stage biopharmaceutical company focused on developing precision biologics using an expanded genetic code.
- PR Newswire
Samsung Biologics awarded Leadership status by CDP for climate action efforts
Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced that it has received the Leadership status and A- rating from the Carbon Disclosure Project (CDP).
